Berberine protects against gefitinib-induced liver injury by inhibiting the HMGB1/TLR4/NF-κB pathway
GEF-induced liver injury is mediated by HMGB1-driven inflammation via the TLR4/NF-κB pathway. BBR provides dose-dependent hepatoprotection by targeting this pathway, suggesting a potential strategy to protect against GEF-induced liver injury among NSCLC patients.
Authors
- Qiongyin Zhang (ORCID: https://orcid.org/0009-0007-9071-4259)
- Xue Ma (ORCID: https://orcid.org/0000-0001-8636-7599)
- Chao Li (ORCID: https://orcid.org/0000-0001-5723-1414)
- Na Li (ORCID: https://orcid.org/0000-0001-6924-8387)
- Ya Chen (ORCID: https://orcid.org/0009-0009-5076-1522)
- Yue Qiu (ORCID: https://orcid.org/0000-0003-4714-9745)
Institutions
- Chongqing University (CN)
- Sichuan Cancer Hospital (CN)
- Chongqing Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-08-26
- DOI
- https://doi.org/10.3389/fphar.2025.1645634
- Citations
- 1
- Primary Topic
- Berberine and alkaloids research
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Sichuan University